Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 6,214 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 6,214 shares of the stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $25.03, for a total value of $155,536.42. Following the completion of the sale, the insider owned 21,479 shares of the company’s stock, valued at approximately $537,619.37. This trade represents a 22.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Price Performance

CSTL stock opened at $25.19 on Thursday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.11 and a current ratio of 5.26. Castle Biosciences, Inc. has a 1 year low of $14.59 and a 1 year high of $44.28. The firm has a market cap of $748.90 million, a P/E ratio of -29.64 and a beta of 1.18. The stock has a 50-day simple moving average of $29.01 and a 200-day simple moving average of $31.92.

Castle Biosciences (NASDAQ:CSTL) last posted its earnings results on Thursday, February 26th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.15. Castle Biosciences had a negative return on equity of 0.89% and a negative net margin of 7.02%.The business had revenue of $81.88 million during the quarter, compared to analyst estimates of $81.19 million. On average, equities analysts predict that Castle Biosciences, Inc. will post 0.44 earnings per share for the current fiscal year.

Institutional Trading of Castle Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the company. Federated Hermes Inc. bought a new stake in shares of Castle Biosciences in the 4th quarter worth $26,000. Kemnay Advisory Services Inc. purchased a new position in shares of Castle Biosciences during the fourth quarter valued at $35,000. Farther Finance Advisors LLC grew its holdings in shares of Castle Biosciences by 139,100.0% during the third quarter. Farther Finance Advisors LLC now owns 1,392 shares of the company’s stock valued at $32,000 after buying an additional 1,391 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Castle Biosciences by 26.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock valued at $55,000 after buying an additional 297 shares in the last quarter. Finally, State of Alaska Department of Revenue purchased a new position in shares of Castle Biosciences during the third quarter valued at $35,000. Institutional investors own 92.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. BTIG Research raised their price objective on Castle Biosciences from $38.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Guggenheim increased their target price on Castle Biosciences from $43.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Lake Street Capital raised their price target on Castle Biosciences from $35.00 to $52.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Weiss Ratings reiterated a “sell (d)” rating on shares of Castle Biosciences in a research note on Monday, December 29th. Finally, Robert W. Baird raised their target price on Castle Biosciences from $41.00 to $44.00 and gave the company an “outperform” rating in a research note on Friday, February 27th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Castle Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $47.57.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.